Amyloid-β and α-Synuclein Immunotherapy: From Experimental Studies to Clinical Trials
Jacqui Nimmo(UK Dementia Research Institute), Jean‐Cosme Dodart(Merritt College), Louise Kelly(University of Southampton), James A. R. Nicoll(University of Southampton), Ajay Verma(Maulana Azad National Institute of Technology), Roxana O. Carare(University of Southampton)
Cited by 40
Related Papers
Immunization reverses memory deficits without reducing brain Aβ burden in Alzheimer's disease model
|Nature Neuroscience|2002|858
A Randomized First‐in‐Human Study With UB‐312, a UBITh® α‐Synuclein Peptide Vaccine
|Movement Disorders|2022|51
Novel antibodies detect additional α-synuclein pathology in synucleinopathies: potential development for immunotherapy
|Alzheimer s Research & Therapy|2020|48
The complement system in neurodegenerative diseases
|Clinical Science|2024|48
The Pattern of AQP4 Expression in the Ageing Human Brain and in Cerebral Amyloid Angiopathy
|International Journal of Molecular Sciences|2020|47